Emerald Health Therapeutics Corporate Presentation Disclaimer The statements

Emerald Health Therapeutics Corporate Presentation

Disclaimer The statements made in this presentation may include forward-looking statements These risks and uncertainties relate to, among other things, changes in laws, regarding the future operations, opportunities or financial performance of emerald health and guidelines relating to medical cannabis and the possible therapeutics (the “company”). Forward looking the federal government; changes in government; increase in the company’s production square statements include the estimated footage; increases in the company’s continued availability of capital financing changes in governmental policy; the and general economic, market or business production; the legalization of recreational cannabis; the size of the medical cannabis conditions; reliance on market and the recreational cannabis market; the company’s expansion goals including facility or scalability, increases in square footage, production and revenue; the company’s position the company to increase production and production square footage; in the cannabis market in respect of demand competition; the company becoming a or consumer perception of the medical cannabis industry; leading brand in cannabis-based products; and the company’s near to long term goals scientific studies on the effects of cannabis; the including increases in patient acquisition, facility expansion, clinical trials and product cannabis markets being less than development as well as market capture, revenue and consolidation of the cannabis the company’s ability market. retain a These forward-looking statements are only estimations based upon the information available to emerald health therapeutics, as of the date of this presentation. Except as required by law, we expressly disclaim any responsibility to publicly update or revise our regulations legalization of cannabis by management; the inability of the company to expand its current obtain additional facility space; failure to obtain approval by health Canada for unfavorable publicity the impact of any negative growth in the medical and recreational anticipated; increased competition in the market place; to meet its near and long-term goals; and the company’s ability to competitive advantage if cannabis is legalized as well as the risk factors set out in the company’s annual information form and other publicly filed disclosure Undue reliance should not be placed on forward looking documents. statements, which speak only as of the date hereof. forward-looking statements, whether as a result of new information, future events or All forward-looking statements contained herein are qualified in their entirety by otherwise. Thus, the forward-looking statements herein involve known and unknown foregoing cautionary statements. Reliance should not be placed on forward risks and uncertainties such that statements, which speak only as of the date hereof. actual future operations, opportunities or financial the looking performance may differ materially from these forward-looking statements. 2

Emerald’s Competitive Advantage How Does Cannabis Work? • The Endocannabinoid System (ECS) • A system that interacts with every aspect of the body Pioneer in Realizing increasing sourcing value in one outdoor of world’s hemp for • Complex set of receptors on. CBD many largest extraction tissues that respond to cannabis growing facilities • Helps regulate mood, appetite, inflammation, homeostasis, etc • Reacts to internal and external cannabinoids Strategic partnerships with large-scale extraction infrastructure and proprietary technology for enhanced biological activity Developing differentiate, consistent and reliable products through Defined Dose. TM program First-mover advantage introducing endocannabinoid - supporting products to natural health consumers factorsgroup of nutritional companies inc. 3

The Endocannabinoid System • System of receptors that interacts with tissues, organs and the immune system • Composed of endocannabinoids and cannabinoid receptors • Helps regulate mood, appetite, inflammation and many other functions that promote health and homeostasis • Cannabis compounds interact with the endocannabinoid system and may have therapeutic effects 4

How the Endocannabinoid System Can Be Affected • Endocannabinoids: cannabinoids produced by our bodies (e. g. , anandamide) • Phytocannabinoids: molecules and compounds produced in plants, such as the cannabis sativa plant (e. g. , medical cannabis, THC, CBD) • Synthetic cannabinoids: derived from natural or synthetic cannabis molecules • Natural non-cannabis substances: can modulate the ECS 8 cannabinoids are the main focus for medical use (only THC is psychotropic) 5

Potential Health Effects of Cannabinoids 6

Pure Sunfarms One of the world’s largest and sophisticated greenhouse growing facilities 1. 1 M sq. ft. state-of-the art greenhouse facility Conservative projected yield of 75, 000 kg

Delta 3: Cultivation in 1. 03 of first 1. 1 M SF Greenhouse Facility • Meticulous attention to growing environment and systems, processing areas and production ramp up • Leading HVAC system; extensive climate management experience & advanced data systems • Automated growing system proven in different crops to provide optimal efficiencies • High-tech light deprivation/ supplementation systems, with individual control of 16 grow rooms 8

Delta 2: Expansion into Second 1. 1 Million Square Foot Greenhouse • Doubles potential production capacity to 150, 000 Kilograms • Less than $1/gram • EHT to purchase 25% of cannabis production from PSF through 2022 • Secured 48 megawatts of electricity from BC Hydro providing a low-cost and reliable power source • Designed with an automated nursery capable of serving both Delta 3 and Delta 2 9

Québec: Verdélite – Wholly Owned • Licensed for Standard Processing • • Extraction, manufacturing, synthesizing, and testing • Distribution hub to eastern Canada and nationwide • 88, 000 square foot purpose-built cannabis production facility • 12 processing and packaging rooms • 23 independent growing rooms 200 cannabis strains 10

Hemp for CBD Extraction • Purchased approximately 500 acres of harvested hemp chaff from established farms in Manitoba and Prince Edward Island in 2018 • Approx. 1000 acres in 2019 – 2022 • Hemp is a very low cost source of CBD 11

Provincial Supply Agreements Country-Wide by Mid-Summer British Columbia 13, 000 kg / 1. 5 years Alberta Saskatchewan Ontario EHT & PSF Quebec Newfoundland Labrador Yukon 12

Strategic Alliance: Factors Group Exclusive arrangement with Canada’s largest nutritional supplement marketer and manufacturer. • Facility capable of 1 M kg of biomass extraction and 600 M softgel capsule production per year • Leverage decades of product development, formulation and innovation experience • Technology transfer of extraction methods and production protocols Over 1 M sf of production facilities, R&D, and quality control laboratories and distribution centres. 13

Intellectual Property & New Product Development Strategy Configurations o EHT patent protected o Exclusive license arrangements + Ingredients 17 patents filled to date o Unique branding opportunities Value-added, differentiated products o EHT patent protected o Trade secrets o Unique formulation(s); Alternative/specialized cannabinoids beyond CBD & THC 14

Developing Intellectual Property Portfolio The path to value-added, differentiated proprietary products Strategic Agreements Indena • • Proprietary extraction technology & capabilities Phytosome® technology to enhance absorption and bioavailability Emerald Health Biotechnology España • Decades of industry- leading cannabis R&D 15

Emerald Health Naturals’ Product Line Harnessing the benefits of cannabis without the marijuana plant • Not cannabis • But supports the endocannabinoid system • Award winning • Approved NPNs from Health Canada • Mid-2019 launch • Grocery, pharmacy natural health stores 16

Advancing Cannabis Science Initiating animal/human studies and benefitting from collaborators’ research • Example: THCA, a non-psychotropic cannabinoid, shows potential in animals to treat neurodegenerative, neuroinflammatory diseases, metabolic disorders and other ailments; EHT product line includes THCA oil product • Animal study underway at UBC • Research conducted at University of Cordoba 17

Emerald Testing and Innovation Laboratory Health Canada Licensed Dealer • Cannabis analytical/testing services for LPs • International government approvals for the import/export of cannabis oils • Exporting to USA • Importing from Netherlands, Colombia and China • Permitted research and development activities beyond producer license 18

Strategic Growth Initiatives in 2019/2020 Significantly increasing production 2019 -20 Large scale sophisticated extraction Animal and clinical studies IP and product development Branded new product launches Distribution agreements/partnerships 19

Capitalization Total Largest Shareholder: Emerald Health Sciences Common Shares O/S 136. 8 M 2* 40. 4 M (29. 5%)3 Options, RSUs and Warrants 20. 2 M 4. 4 M (20%) Fully Diluted 157. 0 M 44. 8 M (28. 6%) Market Cap $589. 99 M 1 Three month averagedaily volume 1. 51 M 4 Cash $52. 9 M 2* Add. Funding $10. 8 M* 119/04/15 218/09/30 319/01/16 4 TSX. V +OTCQX *Financing: $10. 8 M gross proceeds ; 4. 0 M o/s (18/12/07) 22

Peer Comparative Value (market value/kg production capacity) Emerald offers compelling value proposition Top 5 Peers Market Value 2 C$589 M Market value 1 19/04/15 2 WEED, ACB, TLRY*, CRON, AP H 47, 000 Kg Capacity $12, 530 Value/kg ~$9. 3 B average ~265, 440 Kg average ~$41, 750 average Peers 2 trading at ~ 3. 4 x EMH *Tilray stock price converted at USD=1. 34 23

Thank You To learn more please contact: invest@emeraldhealth. ca TSXV: EMH OTCQX: EMHTF Frankfurt: TBD